Vivo Capital LLC acquired a new position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 704,225 shares of the company’s stock, valued at approximately $8,208,000. Verona Pharma PLC American Depositary Share makes up approximately 2.1% of Vivo Capital LLC’s holdings, making the stock its 11th largest position. Vivo Capital LLC owned about 0.11% of Verona Pharma PLC American Depositary Share at the end of the most recent reporting period.

Shares of Verona Pharma PLC American Depositary Share (VRNA) opened at 12.24 on Friday. Verona Pharma PLC American Depositary Share has a 12-month low of $11.03 and a 12-month high of $50.88. The stock’s 50 day moving average is $14.19 and its 200-day moving average is $13.81. The company’s market capitalization is $78.58 million.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last posted its earnings results on Tuesday, August 8th. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.09. Analysts anticipate that Verona Pharma PLC American Depositary Share will post ($2.44) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/13/vivo-capital-llc-invests-8-21-million-in-verona-pharma-plc-american-depositary-share-vrna.html.

A number of research firms have recently issued reports on VRNA. Zacks Investment Research downgraded shares of Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. SunTrust Banks, Inc. began coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They set a “buy” rating and a $26.00 price objective for the company. Stifel Nicolaus began coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They set a “buy” rating and a $22.00 price objective for the company. Jefferies Group LLC reaffirmed a “buy” rating and set a $26.00 price objective on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. Finally, Wedbush began coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They set an “outperform” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Verona Pharma PLC American Depositary Share has a consensus rating of “Buy” and a consensus target price of $22.60.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Want to see what other hedge funds are holding VRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA).

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.